Cannell R J, Knaggs A R, Dawson M J, Manchee G R, Eddershaw P J, Waterhouse I, Sutherland D R, Bowers G D, Sidebottom P J
Natural Products Department, Glaxo Research and Development Limited, Greenford, Middlesex, United Kingdom.
Drug Metab Dispos. 1995 Jul;23(7):724-9.
Screening a range of microorganisms incubated with the angiotensin II antagonist GR117289 resulted in the use of Streptomyces rimosus to generate five related biotransformation products. These comprised three compounds hydroxylated on the aliphatic side chain, one further oxidized to a ketone, and one hydroxylated on the phenyl ring. These microbial metabolites were used as standards to identify a human metabolite detected in plasma and urine, but present in insufficient quantities for full structural characterisation. This further demonstrates how the use of microbial biotransformation systems at an early stage of drug metabolism studies can act as a valuable tool in facilitating identification of minor human metabolites.
筛选一系列与血管紧张素 II 拮抗剂 GR117289 一起培养的微生物,结果发现利用龟裂链霉菌生成了五种相关的生物转化产物。其中包括三种在脂肪族侧链上羟基化的化合物,一种进一步氧化成酮,还有一种在苯环上羟基化。这些微生物代谢产物被用作标准品,以鉴定在血浆和尿液中检测到的一种人体代谢产物,但该代谢产物的量不足以进行完整的结构表征。这进一步证明了在药物代谢研究的早期阶段使用微生物生物转化系统如何能够成为促进鉴定人体微量代谢产物的宝贵工具。